Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.
about
Management of antipsychotic-related weight gainAripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activitiesMetabolic issues in patients affected by schizophrenia: clinical characteristics and medical managementAn evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapineClinical utility of the risperidone formulations in the management of schizophrenia.Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.Polypharmacy for schizophrenia.Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in ratsDose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.Incident somatic comorbidity after psychosis: results from a retrospective cohort study based on Flemish general practice data.Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management.Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.Antipsychotic drugs and obesity.Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder.Genetic and Clinical Factors Affecting Plasma Clozapine ConcentrationObese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness.Correlates of weight gain during long-term risperidone treatment in children and adolescentsAtypical antipsychotic use in patients with dementia: managing safety concerns.Evidence review and clinical guidance for the use of ziprasidone in Canada.The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.Metabolic syndrome in people with schizophrenia: a review.Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow upYouth, caregiver, and prescriber experiences of antipsychotic-related weight gain.Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study.Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials.Prescribing Practices of Quetiapine for Insomnia at a Tertiary Care Inpatient Child and Adolescent Psychiatry Unit: A Continuous Quality Improvement Project.Dietary Fructose and GLUT5 Transporter Activity Contribute to Antipsychotic-Induced Weight Gain.Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome.High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.Monitoring of somatic parameters at outpatient departments for mood and anxiety disorders
P2860
Q24610124-239CF5FA-D14C-438A-A079-7C5EA1786642Q24615556-961609CB-A000-429E-9650-77D7DCF32C98Q26783003-9ECFE7F8-8FD9-4D96-BBE0-526348D02D58Q28543222-4A53ED7A-F9D8-4B48-91D0-80981DA19D9FQ30429721-F16D2B10-F36B-4B47-8991-D9BBEA4EEF24Q30459096-16E45172-D0D4-4F55-9190-1488AFB0D7DEQ33634660-302C50DF-1A19-4A64-BE2B-7A54A91C744BQ33765864-FEECDC77-D4A1-4ACE-A578-7478A253B1DCQ33821379-93D025D1-CB09-43D1-88DE-17CF8231C469Q34086096-5124AF23-20B1-4506-A2D7-36F141B95093Q34543946-DA3CBB9C-3823-41C7-BA76-29981721B22CQ34613195-DFB2CF7C-0EFF-49C6-A3A0-791F130A641CQ34648940-8D88C46B-9950-40CB-AADC-51ACD27388CFQ34761472-2B4C5382-4DDA-4BAA-973C-36D5C8A31E7CQ35745299-DA6791F9-9B01-4A58-A780-B5B96DBC8AA7Q35746655-A2B731D8-09DF-4A1E-8855-9951FAA0B7B7Q36213557-04E73561-2E59-4D96-BDEA-43AD80B26410Q36373562-0D8A2A87-6BE6-4C03-9CA5-B88320392295Q36450333-B7ED17C5-3183-453C-AF62-3E35769CDC6BQ36588607-9F45B28A-EC43-417E-A294-DC270C91A4DBQ37079080-775D8C5B-7EBB-4353-88A9-6D52B6B7834CQ37129646-F16047E0-B90A-4097-8825-5D94A98218E5Q37494988-7173E53A-8776-45E2-AEB5-FCD6955B2645Q37515292-9F5BB30A-38DC-4567-89F7-4FB8F8ABE197Q37589478-34E49F62-1074-460C-90B3-B87A847A6142Q38132164-715930AF-4B05-4888-9572-22D97937AD19Q41018102-98D7D6D3-7C8D-435D-8BD8-155E173344C0Q41703341-6A62040F-4B28-44C9-880E-EA79BD929A55Q41849685-5287EBA3-1890-4F0D-8A43-737579148326Q47152270-5D1DA9A6-5FB7-4BAD-83DC-2152596ECE37Q55479566-AECD0BA1-4825-4165-8F5C-7BB7B60A7216Q58731395-A36083B1-691A-4B1A-81AC-104337CD4138
P2860
Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Are weight gain and metabolic ...... ependent? A literature review.
@en
Are weight gain and metabolic ...... ependent? A literature review.
@nl
type
label
Are weight gain and metabolic ...... ependent? A literature review.
@en
Are weight gain and metabolic ...... ependent? A literature review.
@nl
prefLabel
Are weight gain and metabolic ...... ependent? A literature review.
@en
Are weight gain and metabolic ...... ependent? A literature review.
@nl
P2093
P1476
Are weight gain and metabolic ...... ependent? A literature review.
@en
P2093
Marc De Hert
Ruud van Winkel
Viktoria Simon
P304
P577
2009-07-01T00:00:00Z